
Sponsored • Screening for the use of 5-FU anti-cancer drug
Fully-automated DPD deficiency testing
Each year almost 80,000 new patients in France alone receive fluoropyrimidines, a group of anti-cancer drugs including 5-FU which is normally administered intravenously to treat digestive, breast and head and neck cancer. However, fluoropyrimidines-based chemotherapies can cause severe toxicities (incidence at around 20%) and sometimes lethal toxicity (incidence between 0.1 and 1%) with part of…